Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
412.89 289.44 216.45 178.85 177.16 349.36 159.32 78.00 33.89 59.34
Receivables
44.66 46.53 40.38 44.02 41.46 18.46 19.33 13.17 12.72 8.76
Inventory
20.55 21.75 16.13 14.29 11.23 4.66 6.81 3.40 5.32 3.48
Total current assets
488.38 372.27 285.62 248.64 243.10 375.68 187.69 96.95 53.93 73.63
Property, Plant, Equpment (Net)
22.19 22.95 20.58 17.70 15.10 8.99 8.93 8.94 9.69 11.48
Goodwill and Intangible Assets (Total)
856.30 848.10 791.58 870.76 910.64 62.65 67.74 13.06 14.12 15.19
Long-term assets (Other)
2.55 8.53 6.85 6.17 2.95 2.00 2.04 1.69 0.93 0.74
Total non-current assets
917.64 927.77 829.29 907.79 944.72 81.48 87.53 23.69 24.74 27.41
Total Assets
1,406.02 1,300.04 1,114.91 1,156.42 1,187.83 457.16 275.21 120.64 78.67 101.03
Accounts Payable
4.59 8.63 12.94 11.91 12.36 3.12 2.33 2.52 3.85 2.42
Accrued Expenses
48.80 43.83 38.43 37.77 39.48 11.71 13.73 9.19 8.18 9.11
Current Part of Debt
— — — — 1.13 2.00 1.00 1.36 — —
Current Revenue (Deferred)
1.16 1.67 2.01 2.61 4.65 0.37 — — — —
Other current liabilities
1.33 17.00 2.76 6.25 2.91 12.00 14.00 9.00 8.00 9.11
Total current liabilities
59.94 78.63 61.24 62.61 64.15 16.78 17.47 13.06 12.03 11.53
Long Term Debt (Total)
— — — — — 0.81 0.69 23.93 25.25 25.52
Non-current Revenue (Deferred)
— — — — 0.34 0.83 — 3.90 4.17 4.40
Long Term Tax Liability (Deferred)
0.65 1.23 0.73 4.53 5.59 — — — — —
Non-current Liabilities (Other)
0.26 0.97 1.30 3.43 7.13 7.59 6.09 4.00 4.00 4.40
Total non-current liabilities
36.51 45.44 9.56 18.61 27.16 19.15 18.29 27.82 29.42 29.92
Total liabilities
96.44 124.07 70.80 81.22 91.31 35.93 35.76 40.88 41.44 41.45
Additional Paid In Capital
1,695.34 1,655.96 1,536.17 1,500.19 1,468.68 702.77 486.09 313.80 248.28 239.63
Common Stock (Net)
0.08 0.08 0.07 0.07 0.07 0.06 0.05 0.04 0.03 0.03
Retained Earnings
(377.63) (443.98) (468.12) (393.72) (357.16) (281.59) (246.68) (234.09) (211.09) (180.08)
Common Equity (Total)
1,309.58 1,175.97 1,044.10 1,075.20 1,096.51 421.23 239.46 79.76 37.23 59.58
Shareholders Equity (Total)
1,309.58 1,175.97 1,044.10 1,075.20 1,096.51 421.23 239.46 79.76 37.23 59.58
Shareholders Equity and Liabilities (Total)
1,406.02 1,300.04 1,114.91 1,156.42 1,187.83 457.16 275.21 120.64 78.67 101.03
Shares (Common)
79.36 77.77 73.27 71.96 71.12 58.20 49.63 40.86 34.21 33.76
Shareholders Equity (Tangible)
453.27 327.87 252.53 204.44 185.88 358.58 171.71 66.70 23.10 44.39
Net Debt
(412.89) (289.44) (216.45) (178.85) (176.03) (346.55) (157.62) (52.71) (8.64) (33.82)
Total Debt
— — — 15.00 1.13 2.81 1.69 25.28 25.25 25.52

Fold the line items

In millions of $ except per-share values · columns are period end dates